Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:CYTK NASDAQ:INSM NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$95.50-3.9%$97.52$79.52▼$124.00$24.15B1.361.10 million shs1.51 million shsCYTKCytokinetics$77.09+16.7%$63.81$29.31▼$80.20$9.58B0.382.06 million shs18.08 million shsINSMInsmed$139.44-0.4%$147.89$63.81▼$212.75$30.10B0.892.34 million shs1.24 million shsRVMDRevolution Medicines$147.21-0.5%$110.80$34.00▼$155.70$31.30B1.413.53 million shs3.32 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-4.43%+6.98%-9.89%-7.05%CYTKCytokinetics0.00%+2.84%-5.07%-2.13%+69.61%INSMInsmed0.00%-2.00%-17.96%-15.21%+84.32%RVMDRevolution Medicines0.00%+5.93%+40.72%+45.34%+242.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$95.50-3.9%$97.52$79.52▼$124.00$24.15B1.361.10 million shs1.51 million shsCYTKCytokinetics$77.09+16.7%$63.81$29.31▼$80.20$9.58B0.382.06 million shs18.08 million shsINSMInsmed$139.44-0.4%$147.89$63.81▼$212.75$30.10B0.892.34 million shs1.24 million shsRVMDRevolution Medicines$147.21-0.5%$110.80$34.00▼$155.70$31.30B1.413.53 million shs3.32 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-4.43%+6.98%-9.89%-7.05%CYTKCytokinetics0.00%+2.84%-5.07%-2.13%+69.61%INSMInsmed0.00%-2.00%-17.96%-15.21%+84.32%RVMDRevolution Medicines0.00%+5.93%+40.72%+45.34%+242.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.72Moderate Buy$133.1339.41% UpsideCYTKCytokinetics 2.82Moderate Buy$92.1019.47% UpsideINSMInsmed 3.00Buy$213.2352.92% UpsideRVMDRevolution Medicines 3.10Buy$78.94-46.38% DownsideCurrent Analyst Ratings BreakdownLatest CYTK, RVMD, INSM, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.004/27/2026BNTXBioNTech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$130.004/27/2026RVMDRevolution Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026RVMDRevolution Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RVMDRevolution Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CYTKCytokinetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026RVMDRevolution Medicines Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/17/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$212.004/16/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$230.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.87B8.42$1.31 per share73.06$96.59 per share0.99CYTKCytokinetics$88.04M108.79N/AN/A($5.39) per share-14.30INSMInsmed$606.42M49.63N/AN/A$3.46 per share40.30RVMDRevolution MedicinesN/AN/AN/AN/A$8.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.24N/AN/AN/A-38.09%-4.76%-4.15%5/5/2026 (Estimated)CYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-891.60%N/A-49.62%5/5/2026 (Estimated)INSMInsmed-$1.28B-$6.41N/A108.94N/A-210.54%-168.36%-57.33%5/7/2026 (Estimated)RVMDRevolution Medicines-$1.13B-$5.91N/AN/AN/AN/A-63.10%-48.13%5/6/2026 (Estimated)Latest CYTK, RVMD, INSM, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INSMInsmed-$0.9692N/AN/AN/A$299.05 millionN/A5/6/2026Q1 2026RVMDRevolution Medicines-$1.83N/AN/AN/A$2.43 millionN/A5/5/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.43 million$136.59 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million2/25/2026Q4 2025RVMDRevolution Medicines-$1.56-$1.86-$0.30-$1.86$3.89 millionN/A2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/19/2026Q4 2025INSMInsmed-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 million2/14/2026Q4 2025BNTXBioNTechN/A-$0.3870N/A-$1.47N/A$1.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.60%N/AN/A N/ACYTKCytokineticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.017.547.49CYTKCytokineticsN/A4.534.53INSMInsmed0.763.833.54RVMDRevolution Medicines0.167.147.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%CYTKCytokineticsN/AINSMInsmedN/ARVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%CYTKCytokinetics2.60%INSMInsmed2.10%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableCYTKCytokinetics250124.24 million121.01 millionOptionableINSMInsmed1,664215.85 million211.32 millionOptionableRVMDRevolution Medicines250212.59 million195.16 millionOptionableCYTK, RVMD, INSM, and BNTX HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. $RVMD Shares Sold by State of New Jersey Common Pension Fund DMay 5 at 5:31 AM | marketbeat.comRevolution Medicines (RVMD) to Release Quarterly Earnings on WednesdayMay 4 at 6:05 AM | americanbankingnews.comRevolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityMay 2 at 4:11 PM | insidermonkey.comRevolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This StockMay 2 at 12:44 PM | finance.yahoo.comJennison Associates LLC Takes $24.31 Million Position in Revolution Medicines, Inc. $RVMDMay 2 at 6:49 AM | marketbeat.comRevolution Medicines wins FDA nod to provide early access to cancer therapyMay 1, 2026 | seekingalpha.comUS FDA authorizes early access to Revolution's pancreatic cancer pillMay 1, 2026 | reuters.comRevolution Medicines, Inc. $RVMD Shares Bought by Vanguard Group Inc.May 1, 2026 | marketbeat.comRevolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026April 29, 2026 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Has $5.23 Million Stake in Revolution Medicines, Inc. $RVMDApril 29, 2026 | marketbeat.comPictet Asset Management Holding SA Reduces Stake in Revolution Medicines, Inc. $RVMDApril 29, 2026 | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Bought by UBS Group AGApril 29, 2026 | marketbeat.comRevolution Medicines (RVMD) Expected to Announce Earnings on WednesdayApril 29, 2026 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst UpgradeApril 28, 2026 | marketbeat.comRevolution Medicines Trial Updates Spark Fresh Interest In RAS Focused PipelineApril 28, 2026 | finance.yahoo.comRevolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at Truist FinancialApril 28, 2026 | marketbeat.comThere's a Revolution in Cancer. But Can Big Pharma Afford It?April 28, 2026 | wsj.comCalamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMDApril 28, 2026 | marketbeat.comB. Metzler seel. Sohn & Co. AG Cuts Stock Position in Revolution Medicines, Inc. $RVMDApril 27, 2026 | marketbeat.comLifesci Capital Has Bullish Forecast for RVMD Q2 EarningsApril 27, 2026 | marketbeat.comWest Michigan Advisors LLC Makes New $606,000 Investment in Revolution Medicines, Inc. $RVMDApril 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTK, RVMD, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$95.50 -3.85 (-3.88%) Closing price 04:00 PM EasternExtended Trading$95.50 0.00 (0.00%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Cytokinetics NASDAQ:CYTK$77.09 +11.04 (+16.71%) Closing price 04:00 PM EasternExtended Trading$76.40 -0.69 (-0.90%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Insmed NASDAQ:INSM$139.44 -0.57 (-0.41%) Closing price 04:00 PM EasternExtended Trading$139.51 +0.07 (+0.05%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Revolution Medicines NASDAQ:RVMD$147.21 -0.69 (-0.47%) Closing price 04:00 PM EasternExtended Trading$147.25 +0.04 (+0.03%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
